Pyxis Oncology, Inc. (NasdaqGS: PYXS)
Health Care · Biotechnology · US
$3.06
-0.65% today · +121.6% 1Y
Pyxis Oncology, Inc. (NasdaqGS: PYXS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $256.90M and employs 56 people.
Over the last twelve months the share price has gained 121.6%, trading between 1.03 and 5.55.
Tweenvest scores Pyxis Oncology, Inc. across four factors: quality 28/100, value 70/100. Its strongest factor is value.
PYXS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $256.90M
- Revenue (TTM)
- $11.04M
- P/E
- —
- EPS
- -1.40
- Dividend yield
- —
- Beta (5Y)
- 1.32
- 52-week high
- $5.55
- 52-week low
- $1.03
- Avg volume (3M)
- —
- Shares outstanding
- 83.41M
- Employees
- 56
- Next earnings
- —
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
- ISIN
- US7473241013
- Founded
- 2018
- Listed since
- Oct 8, 2021
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.